Systematic review evaluates palbociclib's impact on cell cycle in HPV-negative tumors, suggesting enhanced outcomes.
This study evaluates the action of Palbociclib in the cell cycle of HPV-negative head and neck squamous cell carcinoma. Initially approved for HER2- and HR + breast cancer. Palbociclib induces cellular senescence, increases the efficacy of Cetuximab, restores p16 function and decreases phosphorylated Rb, suggesting an improvement in survival in both cancers.
No takes yet. Share an insight, caveat, or question.
Teixeira et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: